中华核医学杂志
中華覈醫學雜誌
중화핵의학잡지
CHINESE JOURNAL OF NUCLEAR MEDICINE
2010年
2期
110-115
,共6页
石怡珍%周小林%徐巧玲%刘增礼%杨仪%申咏梅
石怡珍%週小林%徐巧玲%劉增禮%楊儀%申詠梅
석이진%주소림%서교령%류증례%양의%신영매
小细胞肺癌%抗体,单克隆%胃泌素释放肽%放射性核素显像%放射免疫疗法%小鼠,裸
小細胞肺癌%抗體,單剋隆%胃泌素釋放肽%放射性覈素顯像%放射免疫療法%小鼠,裸
소세포폐암%항체,단극륭%위비소석방태%방사성핵소현상%방사면역요법%소서,라
Small cell lung carcinoma%Antibodies,monoclonal%Gastrin-releasing peptide%Radionuclide imaging%Radioimmunotherapy%Mice,Nude
目的 了解~(131)I标记的胃泌素释放肽前体(ProGRP)单克隆抗体E-B_5在荷小细胞肺癌裸鼠的体内分布及放射免疫显像情况,观察~(131)I-E-B_5对荷小细胞肺癌裸鼠移植瘤的生长抑制作用.方法 (1)分别建立荷小细胞肺癌、荷肺腺癌及荷大肠癌裸鼠模型.(2)自荷小细胞肺癌裸鼠尾静脉注射~(131)I-E-B_5后1,12,24,48,72和96 h处死裸鼠并取各主要脏器组织,计算各时间点的每克组织百分注射剂量率(%ID/g)和肿瘤/非肿瘤放射性(T/NT)比值.(3)分别对荷小细胞肺癌、荷肺腺癌和荷大肠癌裸鼠模型进行~(131)I-E-B_5放射免疫显像,观察移植瘤的显影情况,并计算移植瘤体/对侧相同部位的放射性(T/B)比值.(4)以未经任何治疗处理组为对照,采用瘤内注射法观察比较3.7,7.4,14.8和22.2 MBq~(131)I-E-B_5和Na~(131)I对荷小细胞肺癌裸鼠移植瘤的抑制作用.采用SPSS 13.0软件处理数据,行两样本均数t检验.结果 (1)体内分布研究示:注射后72 h,荷小细胞肺癌裸鼠移植瘤体的放射性摄取达到最高值,为(14.1±2.9)%ID/g,高于其他脏器及组织(t=4.11～8.58,P均<0.05),瘤体与各脏器组织的T/NT比值随时间延长而逐渐升高,72 h时瘤体与肌肉组织的T/NT比值高达4.67±0.66.(2)放射免疫显像发现:注射~(131)I-E-B_5后24 h荷小细胞肺癌裸鼠移植瘤部位放射性明显聚集,随时间延长放射性浓聚程度逐渐增强,72至96 h时最为清晰.荷肺腺癌裸鼠移植瘤局部无明显的放射性浓聚.荷大肠癌裸鼠移植瘤模型显像结果与荷小细胞肺癌裸鼠模型显像结果类似,但其T/B比值低于荷小细胞肺癌裸鼠模型(t=4.29,P<0.01).注射后72 h,荷小细胞肺癌、荷大肠癌及荷肺腺癌裸鼠的T/B比值分别为5.27±0.97,2.28±0.72和1.26±0.65.(3)~(131)I-E-B_5对荷小细胞肺癌移植瘤的生长抑制作用明显大于Na~(131)I(t=2.88～17.77,P均<0.05).结论 ~(131)I-E-B_5对小细胞肺癌有较好的靶向作用,可以抑制小细胞肺癌移植的生长并破坏肿瘤组织,有望成为一种较为理想的小细胞肺癌放射免疫显像及放射免疫治疗药物,值得进一步深入研究.
目的 瞭解~(131)I標記的胃泌素釋放肽前體(ProGRP)單剋隆抗體E-B_5在荷小細胞肺癌裸鼠的體內分佈及放射免疫顯像情況,觀察~(131)I-E-B_5對荷小細胞肺癌裸鼠移植瘤的生長抑製作用.方法 (1)分彆建立荷小細胞肺癌、荷肺腺癌及荷大腸癌裸鼠模型.(2)自荷小細胞肺癌裸鼠尾靜脈註射~(131)I-E-B_5後1,12,24,48,72和96 h處死裸鼠併取各主要髒器組織,計算各時間點的每剋組織百分註射劑量率(%ID/g)和腫瘤/非腫瘤放射性(T/NT)比值.(3)分彆對荷小細胞肺癌、荷肺腺癌和荷大腸癌裸鼠模型進行~(131)I-E-B_5放射免疫顯像,觀察移植瘤的顯影情況,併計算移植瘤體/對側相同部位的放射性(T/B)比值.(4)以未經任何治療處理組為對照,採用瘤內註射法觀察比較3.7,7.4,14.8和22.2 MBq~(131)I-E-B_5和Na~(131)I對荷小細胞肺癌裸鼠移植瘤的抑製作用.採用SPSS 13.0軟件處理數據,行兩樣本均數t檢驗.結果 (1)體內分佈研究示:註射後72 h,荷小細胞肺癌裸鼠移植瘤體的放射性攝取達到最高值,為(14.1±2.9)%ID/g,高于其他髒器及組織(t=4.11～8.58,P均<0.05),瘤體與各髒器組織的T/NT比值隨時間延長而逐漸升高,72 h時瘤體與肌肉組織的T/NT比值高達4.67±0.66.(2)放射免疫顯像髮現:註射~(131)I-E-B_5後24 h荷小細胞肺癌裸鼠移植瘤部位放射性明顯聚集,隨時間延長放射性濃聚程度逐漸增彊,72至96 h時最為清晰.荷肺腺癌裸鼠移植瘤跼部無明顯的放射性濃聚.荷大腸癌裸鼠移植瘤模型顯像結果與荷小細胞肺癌裸鼠模型顯像結果類似,但其T/B比值低于荷小細胞肺癌裸鼠模型(t=4.29,P<0.01).註射後72 h,荷小細胞肺癌、荷大腸癌及荷肺腺癌裸鼠的T/B比值分彆為5.27±0.97,2.28±0.72和1.26±0.65.(3)~(131)I-E-B_5對荷小細胞肺癌移植瘤的生長抑製作用明顯大于Na~(131)I(t=2.88～17.77,P均<0.05).結論 ~(131)I-E-B_5對小細胞肺癌有較好的靶嚮作用,可以抑製小細胞肺癌移植的生長併破壞腫瘤組織,有望成為一種較為理想的小細胞肺癌放射免疫顯像及放射免疫治療藥物,值得進一步深入研究.
목적 료해~(131)I표기적위비소석방태전체(ProGRP)단극륭항체E-B_5재하소세포폐암라서적체내분포급방사면역현상정황,관찰~(131)I-E-B_5대하소세포폐암라서이식류적생장억제작용.방법 (1)분별건립하소세포폐암、하폐선암급하대장암라서모형.(2)자하소세포폐암라서미정맥주사~(131)I-E-B_5후1,12,24,48,72화96 h처사라서병취각주요장기조직,계산각시간점적매극조직백분주사제량솔(%ID/g)화종류/비종류방사성(T/NT)비치.(3)분별대하소세포폐암、하폐선암화하대장암라서모형진행~(131)I-E-B_5방사면역현상,관찰이식류적현영정황,병계산이식류체/대측상동부위적방사성(T/B)비치.(4)이미경임하치료처리조위대조,채용류내주사법관찰비교3.7,7.4,14.8화22.2 MBq~(131)I-E-B_5화Na~(131)I대하소세포폐암라서이식류적억제작용.채용SPSS 13.0연건처리수거,행량양본균수t검험.결과 (1)체내분포연구시:주사후72 h,하소세포폐암라서이식류체적방사성섭취체도최고치,위(14.1±2.9)%ID/g,고우기타장기급조직(t=4.11～8.58,P균<0.05),류체여각장기조직적T/NT비치수시간연장이축점승고,72 h시류체여기육조직적T/NT비치고체4.67±0.66.(2)방사면역현상발현:주사~(131)I-E-B_5후24 h하소세포폐암라서이식류부위방사성명현취집,수시간연장방사성농취정도축점증강,72지96 h시최위청석.하폐선암라서이식류국부무명현적방사성농취.하대장암라서이식류모형현상결과여하소세포폐암라서모형현상결과유사,단기T/B비치저우하소세포폐암라서모형(t=4.29,P<0.01).주사후72 h,하소세포폐암、하대장암급하폐선암라서적T/B비치분별위5.27±0.97,2.28±0.72화1.26±0.65.(3)~(131)I-E-B_5대하소세포폐암이식류적생장억제작용명현대우Na~(131)I(t=2.88～17.77,P균<0.05).결론 ~(131)I-E-B_5대소세포폐암유교호적파향작용,가이억제소세포폐암이식적생장병파배종류조직,유망성위일충교위이상적소세포폐암방사면역현상급방사면역치료약물,치득진일보심입연구.
Objective To explore the biodistribution, radioimmunoimaging and anti-tumor effect of ~(131)I labeling anti-progastrin-releasing peptide_((31-98)) (ProGRP_((31-98))) monoclonal antibody E-B_5 (~(131)I-E-B_5) in nude mice bearing human small cell lung cancer (SCLC).Methods Nude mice bearing human SCLC were sacrificed at 1, 12, 24, 48, 72 and 96 h after injection with ~(131) I-E-B_5 through tail vein.Their organs were harvested for calculating percentage activity of injection dose per gram of tissue (% ID/g) and the ra-dioactivity ratio of tumor/non-tumor (T/NT).Continuous images of the nude mice bearing SCLC, lung ade-nocarcinoma and colon cancer were carried out respectively at 1, 4, 8, 10, 24, 48, 72 and 96 h after injec-tion of ~(131)I-E-B_5.Transplantation tumor images were then observed and the radioactivity ratio of tumor/back-ground (T/B) was calculated.The nude mice bearing SCLC were divided into 3 groups, including ~(131)I-E-B_5, Na~(131)I and control groups.From the first to the fourth week after intratumoral injections, the tumor sizes were measured and compared.Continuous variables were expressed as x±s and compared by t-test with SPSS 13.0 software.Results (1) The peak uptake of ~(131)-E-B_5 in xenograft tumor of SCLC was at 72 h at-ter injection ((14.1±2.9) % ID/g) with a T/B ratio of 4.67±0.66.(2) Accumulation of ~(131)I-E-B_5 at xenograft tumor of SCLC was visualized at 24 h with highest T/B ratio at 72 h to 96 h post-injection.At 72 h after injection, the T/B ratio of xenograft tumor of SCLC, colon cancer and lung adenocarcinoma was 5.27± 0.97, 2.28±0.72 and 1.26±0.65, respectively and was consistent with the biodistribution in nude mice bearing SCLC.(3) The inhibition ratio of SCLC of the ~(131)I-E-B_5 group was conspicuous higher than that of Na~(131)I group (t: 2.88 to 17.77, all P <0.05).Conclusion ~(131)I-E-B_5 could effectively target SCLC and inhibit the growth of tumor, therefore was a promising radioimmunoimaging and radioimmunotherapy radio-pharmaceutical for SCLC.
